SMARCA2 (BRM) Inhibitor
LY4050784

Zhang B, et al1; Jancewicz I, et al2; Papillon JPN, et al3; Helming KC, et al4; Wilson BG, et al5; Hoffman GR, et al6
Target
Molecule
Clinical Development
References
- Zhang B, et al. Nat Commun. 2021;12(1):1275.
- Jancewicz I, et al. Epigenetics Chromatin. 2019;12(1):68.
- Papillon JPN, et al. J Med Chem. 2018;61(22):10155-10172.
- Helming KC, et al. Cancer Cell. 2014;26(3):309-317.
- Wilson BG, et al. Mol Cell Biol. 2014;34(6):1136-1144.
- Hoffman GR, et al. Proc Natl Acad Sci U S A. 2014;111(8):3128-3133.
- Dagogo-Jack I, et al. J Thorac Oncol. 2020;15(5):766-776.
- Lee JY, et al. Discovery of selective BRM (SMARCA2) ATPase inhibitors for the treatment of BRG1 (SMARCA4) mutant cancers. Presented at: AACR Annual Meeting; April 5-10, 2024; San Diego, CA.

Zhang B, et al1; Jancewicz I, et al2; Papillon JPN, et al3; Helming KC, et al4; Wilson BG, et al5; Hoffman GR, et al6
or visit www.clinicaltrials.gov for more information on this trial
For Healthcare Professionals
The information contained in LillyOncologyPipeline.com is technical in nature and intended for Healthcare Professionals in the United States only. If you are a US Healthcare Professional, click the “Continue” button below.
Yes, I am a US Healthcare Professional and would like to continue.